News und Analysen
Why Kite Pharma Soared 64.8% in August
Shares of Kite Pharma (NASDAQ: KITE), a clinical-stage biotech focused on chimeric antigen receptor T-cell (CAR-T therapy), skyrocketed 65% in August, according to data from S&P Global Market....
Why Kite Pharma Soared 64.8% in August
Shares of Kite Pharma (NASDAQ: KITE), a clinical-stage biotech focused on chimeric antigen receptor T-cell (CAR-T therapy), skyrocketed 65% in August, according to data from S&P Global Market....
Why Kite Pharma Soared 64.8% in August
Shares of Kite Pharma (NASDAQ: KITE), a clinical-stage biotech focused on chimeric antigen receptor T-cell (CAR-T therapy), skyrocketed 65% in August, according to data from S&P Global Market....
Here's Why Voyager Therapeutics Gained as Much as 24.9% Today
Shares of clinical-stage biopharma Voyager Therapeutics (NASDAQ: VYGR) popped nearly 25% today after the company announced positive results for a phase 1b trial investigating the potential of its....
Why Sarepta Therapeutics Stock Is Rising Today
Shares of mid-cap biotech Sarepta Therapeutics (NASDAQ: SRPT) marched almost 11% higher Wednesday morning on elevated volume. The stock's rally was catalyzed by news of encouraging results from an....
Here's Why Novo Nordisk A/S Gained 12% in August
Shares of Danish pharma giant Novo Nordisk A/S (NYSE: NVO) rose 11.7% in August, according to data from S&P Global Market Intelligence. Investors were relieved to see that the sales stall the....
Upcoming Data Releases Fueled Strong Gains in These 2 Marijuana Stocks Last Week
Though speculators' eyes may be on bitcoin and other cryptocurrencies at the moment, arguably no group of stock-based equities has been stronger over the trailing year than marijuana stocks. If we....
Could These 2 Biotech Stocks Really Double Your Money?
Investment-bank analysts have been slapping lofty price targets on small-cap biotech stocks recently. More than a few targets I've seen recently suggest you could easily double your money or....
7 Medical Conditions That Will Be Lining Big Pharma's Pockets by 2020
Image source: Getty Images.Imagine a stack of dollar bills reaching from the ground to more than 95,000 miles into the sky -- nearly four-tenths of the way to the moon. That stack would total $1.4....
7 Medical Conditions That Will Be Lining Big Pharma's Pockets by 2020
Image source: Getty Images.Imagine a stack of dollar bills reaching from the ground to more than 95,000 miles into the sky -- nearly four-tenths of the way to the moon. That stack would total $1.4....
Why Exact Sciences Shares Rallied 10.2% in August
After the company reported better-than-expected top- and bottom-line second-quarter results in late July and updated investors on its strategy at Cannacord's 37th annual growth conference on Aug.....
Here's Why Cellectis SA Fell as Much as 31.6% Today
Shares of biopharma Cellectis (NASDAQ: CLLS) fell nearly 32% today after the company announced that the U.S. Food and Drug Administration had placed a clinical hold on its second leading product....
Here's Why Insmed Incorporated Is Skyrocketing
Investors in Insmed (NASDAQ: INSM) are having an incredible start to the short trading week. Shares of the rare disease focused biotech are up 110% as of 11:15 a.m. EDT, after the company....
The 2 Major Catalysts Behind Myriad Genetics, Inc.'s 26% Gain in August
Shares of Myriad Genetics (NASDAQ: MYGN), a leading developer of molecular diagnostic tests, surged by 26% during the month of August, according to data from S&P Global Market Intelligence.....
The Key Reason Incyte Corporation Added $850 Million in Market Cap in August
Shares of Incyte (NASDAQ: INCY), a large-cap biotech company primarily focused on developing therapies to treat cancer and inflammatory diseases, tacked on more than $4 per share, or $850 million....
The Key Reason Incyte Corporation Added $850 Million in Market Cap in August
Shares of Incyte (NASDAQ: INCY), a large-cap biotech company primarily focused on developing therapies to treat cancer and inflammatory diseases, tacked on more than $4 per share, or $850 million....
Why This Marijuana Stock Crashed 18.5% in August
Arizona's attorney general is suing Insys Therapeutics (NASDAQ: INSY) over its marketing of the fentanyl opioid spray, Subsys, and that news caused the company's shares to tumble 18.5% in August,....
Why Juno Therapeutics Shares Vaulted 46% Higher in August
After Gilead Sciences (NASDAQ: GILD) scooped up competitor Kite Pharma (NASDAQ: KITE) for $11.9 billion and Novartis (NYSE: NVS) secured an approval from the Food and Drug Administration for....
Why Juno Therapeutics Shares Vaulted 46% Higher in August
After Gilead Sciences (NASDAQ: GILD) scooped up competitor Kite Pharma (NASDAQ: KITE) for $11.9 billion and Novartis (NYSE: NVS) secured an approval from the Food and Drug Administration for....
Why Juno Therapeutics Shares Vaulted 46% Higher in August
After Gilead Sciences (NASDAQ: GILD) scooped up competitor Kite Pharma (NASDAQ: KITE) for $11.9 billion and Novartis (NYSE: NVS) secured an approval from the Food and Drug Administration for....
BASTIDE : Cessation du contrat de liquidité contracté avec Gilbert Dupont - Mise en oeuvre d'un contrat de liquidité avec Natixis (ERRATUM)
Le 4 septembre 2017
A effet du 4 septembre 2017, il a été mis fin au contrat de liquidité confié par la société Bastide Groupe à Gilbert Dupont.
A cette date, les moyens suivants figuraient....
BASTIDE : Nombre d'actions et de droits de vote au 31 aout 2017
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12 avenue de la Dame, Zone Euro 2000
30132 Caissargues
RCS de NIMES N° B 305 635 039
DROITS DE....
BASTIDE : Cessation du contrat de liquidité contracté avec Gilbert Dupont - Mise en oeuvre d'un contrat de liquidité avec Natixis
Le 4 septembre 2017
A effet du 4 septembre 2017, il a été mis fin au contrat de liquidité confié par la société Bastide Groupe à Gilbert Dupont.
A cette date, les moyens suivants figuraient....
Better Buy: Gilead Sciences, Inc. vs. Johnson & Johnson
I bought my shares of Johnson & Johnson (NYSE: JNJ) and Gilead Sciences, Inc. (NASDAQ: GILD) long ago, when they were trading far lower than they are today. If I had to choose one to keep and....
Better Buy: Gilead Sciences, Inc. vs. Johnson & Johnson
I bought my shares of Johnson & Johnson (NYSE: JNJ) and Gilead Sciences, Inc. (NASDAQ: GILD) long ago, when they were trading far lower than they are today. If I had to choose one to keep and....